![]() There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties, including statements concerning Company's application for listing on the OTCQB. This news release contains forward-looking statements. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit Contact Information ![]() Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. ![]() Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. The OTCQB Market is an established financial market in the United States for promising, investor-focused companies based in America or internationally. Novamind intends to apply to list its common shares on the OTCQB Market in the near future. The Company's common shares will continue to trade on the Canadian Securities Exchange under the symbol "NM". TORONTO, ON / ACCESSWIRE / Febru/ Novamind Inc., (CSE:NM)(OTC PINK:NVMDF) ("Novamind" or the "Company") a mental health company specialized in psychedelic medicine, announces that its common shares, previously listed for trading on the OTC Pink Market in the United States under the symbol "HNLMF", are to commence trading on the OTC Pink Market under the symbol "NVMDF" effective February 19, 2021. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |